BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 8149794)

  • 1. [Standard of chemotherapy in ovarian cancer].
    Pfleiderer A; Meerpohl HG
    Chirurg; 1994 Jan; 65(1):18-22. PubMed ID: 8149794
    [No Abstract]   [Full Text] [Related]  

  • 2. [Secondary debulking operation in ovarian cancer].
    Jänicke F; Schattenmann G; Kuhn W; Graeff H; Siewert JR
    Chirurg; 1994 Jan; 65(1):10-7. PubMed ID: 8149793
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is there a standard therapy in advanced ovarian carcinoma?].
    Köchli OR
    Praxis (Bern 1994); 1999 Jan; 88(4):123-5. PubMed ID: 10067114
    [No Abstract]   [Full Text] [Related]  

  • 4. Current aspects of adjuvant therapy of early stage ovarian cancer.
    McGuire WP
    Zentralbl Gynakol; 1998; 120(3):93-7. PubMed ID: 9556898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
    Munkarah A
    Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Personal experiences in the treatment of stage III and IV ovarian cancer].
    Welponer F; Delucca A; Messini S
    Gynakol Rundsch; 1990; 30 Suppl 1():45-8. PubMed ID: 2079298
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of chemotherapy in gynecologic cancer.
    Tropé C; Kristensen G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-1-S15-22. PubMed ID: 9346216
    [No Abstract]   [Full Text] [Related]  

  • 9. LTE-commenting on "Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer" (90: 163-9).
    Eisenkop SM
    Gynecol Oncol; 2004 Mar; 92(3):1017-8; author reply 1018-9. PubMed ID: 14984983
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Second-look and third-look laparotomies in follow-up of ovarian cancer. A critical review of 6 years' experience].
    Schneider J; Erasun F; Hervas JL; Miñambres JL
    Zentralbl Gynakol; 1987; 109(4):235-42. PubMed ID: 3591059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic Sertoli-Leydig cell ovarian cancer manifested as a frontal sinus mass.
    Campisi P; Cheski P
    J Otolaryngol; 1998 Dec; 27(6):361-2. PubMed ID: 9857323
    [No Abstract]   [Full Text] [Related]  

  • 13. [Surgery of malignant tumors of the ovary].
    Mossetti C; Carnino F; Cottini M; Iskra L; Dadone D
    Minerva Ginecol; 1987 Sep; 39(9):615-23. PubMed ID: 3317132
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy in epithelial ovarian cancer.
    Wang J; Li AJ; Karlan BY
    Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy of ovarian carcinoma].
    Dittrich C
    Wien Med Wochenschr; 1996; 146(1-2):23-34. PubMed ID: 8835492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late recurrence in ovarian dysgerminoma with successful response to standard adjuvant chemotherapy: a case report and review of the literature.
    Jeyakumar A; Cabeza R; Hindenburg A
    Gynecol Oncol; 2001 May; 81(2):314-7. PubMed ID: 11330968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of ovarian endodermal sinus tumor relapsed into remained ovary at 4 years and 9 months after the first operation].
    Kamiya N; Kawai M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jul; 44(7):889-92. PubMed ID: 1380054
    [No Abstract]   [Full Text] [Related]  

  • 18. [Secondary cytoreductions in the treatment of ovarian cancers].
    Zylberberg B; Dormont D; Janklewicz S; Daraï E; Madelenat P; Antoine JM
    Gynecol Obstet Fertil; 2000 Feb; 28(2):127-36. PubMed ID: 10758587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy and prognostic significance of the size of the remaining tumor in ovarian cancer].
    Petru E; Lahousen M; Pickel H; Stettner H
    Gynakol Rundsch; 1989; 29 Suppl 2():413-4. PubMed ID: 2613067
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy for ovarian cancer: an evidence-based approach.
    Geisler JP; Manahan KJ; Wiemann MC
    Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.